ANSWER: FUNDIC GLAND POLYPS

In this patient, more than 100 polyps were seen during esophagogastroduodenoscopy and at least 30 were removed for biopsy. Polyp biopsies showed no evidence of Helicobacter pylori microorganisms or dysplasia, and all were found to be inflammatory polyps of the gastric fundic type. The patient's proton pump inhibitor (PPI) was discontinued. The patient was seen for follow-up 8 months later and reported improvement of symptoms. Repeated esophagogastroduodenoscopy (Figure 3) showed remarkable resolution of the gastric polyps. Results of a colonoscopy performed to evaluate for colonic polyps were negative. Incidentally, multiple gallbladder polyps were found on ultrasonography of the right upper quadrant; the largest gallbladder polyp was 7 mm. The patient was scheduled to have a laparoscopic cholecystectomy to eliminate any possibility of malignancy.

Figure 3. Follow-up esophagogastroduodenoscopy showed the fundus with a few small, scattered, hyperplastic polyps. The remainder of the stomach appeared normal.

Fundic gland polyps (FGPs) are usually smaller than 1 cm and are smooth, glassy, and often transparent in appearance. They are typically found in the fundus and upper body of the stomach. Histologically, they have fundic mucosa with dilated cystic glands, parietal cell protrusions, and parietal cell hyperplasia. Treatment of FGPs is based on the size of the polyps. For those larger than 1 cm, biopsies are performed and PPI use is discontinued. For those between 0.5 and 1.0 cm, biopsies are done. For those smaller than 0.5 cm, surveillance is performed in 3 to 6 months.

The FGPs are usually detected incidentally during endoscopic evaluation for abdominal pain, dyspepsia, or chronic reflux as in our patient. They are the most common gastric polyps in Western countries, found incidentally in 2% of all endoscopic studies.1- 4 They may be sporadic, may occur in association with PPI use, or may be present in patients with familial adenomatous polyposis.1,5- 8 Sporadic and PPI-associated FGPs are believed to have a low malignant potential in contrast to the familial adenomatous polyposis–associated FGPs. The incidence of FGPs has increased owing to the overuse of PPIs in the treatment of acid-related disorders such as gastroesophageal reflux disease, peptic ulcer disease, and H pylori infection; they are associated with PPI use in up to 1.9% of the general population. Increased risk of FGPs was noted with PPI use longer than 1 year (odds ratio = 2.2; 95% CI, 1.3-3.8) as compared with short-term use (odds ratio = 1.0; 95% CI, 0.5-1.8).5 Also, an increased risk of dysplasia in FGPs was suggested in a case-control study involving patients with familial adenomatous polyposis receiving a PPI.5,9

The formation of FGPs is postulated to be a result of hypergastrinemia leading to parietal cell hyperplasia and protrusion into the lumen of the gland. Long-term PPI use is associated with a 4-fold increased risk of FGPs. Several studies have documented that discontinuation of the PPI results in the disappearance of the polyps.7,8 The true clinical significance of these FGPs remains elusive. Further long-term prospective studies are required to elucidate the long-term risks of prolonged PPI use.

Correspondence

The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with
the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.

Indicate what change(s) you will implement in your practice, if any, based on this CME course.

Your quiz results:

The filled radio buttons indicate your responses. The preferred responses are highlighted

For CME Course:
A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes

Indicate what changes(s) you will implement in your practice, if any, based on this
CME course.

Instructions

Thank you for submitting a comment on this article. It will be reviewed by JAMA Surgery editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.

Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.

* = Required Field

Comment Author(s)* (if multiple authors, separate
names by comma)

Example: John Doe

Affiliation & Institution*

Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.

This feature is provided as a courtesy. By using it you agree that that you are requesting the material solely for personal, non-commercial use, and that it is subject to the AMA's Terms of Use. The information provided in order to email this article will not be shared, sold, traded, exchanged, or rented. Please refer to The JAMA Network's Privacy Policy for additional information.

Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.